Neurology · Pain ManagementRegulatory Approvalregulatorynear-term

FDA Approves Pregabalin Application ANDA219593 by Unichem

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/2/2026, 12:32:15 PM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Unichem's ANDA219593 for Pregabalin signifies a new competitor entering the pain management market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the implications for existing Pregabalin products and adjust strategies accordingly. Regulatory context from FDA (FDA AP — PREGABALIN (SUPPL)) supports the near-term read. Assessment grounded in 7 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing Pregabalin products. The strongest clinical anchor is Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia (ClinicalTrials.gov), sub-indication match (pain). In pain, 3 regulatory and 1 competitive items passed relevance filtering for Unichem.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). This approval allows Unichem to market Pregabalin, increasing competition in the pain management market.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PREGABALIN (SUPPL) (FDA). Entity match (pregabalin); Regulatory pathway relevance (nda). This approval indicates a significant regulatory milestone that could influence future applications and market dynamics in the neurology and pain management sectors.

Key Risks

Elevated high regulatory exposure for Unichem could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The entry of Unichem into the market could lead to increased competition, potentially affecting revenue and market share for current Pregabalin products.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing Pregabalin products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and any subsequent pricing strategies from Unichem.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Development of Pain Control Options Menu for IUD Insertion
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Care
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Approves QLONILIK (Clonidine Hydrochloride) NDA221094
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Approves Sitagliptin and Metformin Hydrochloride Combination
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Management of uterine fibroids: opinions on interventions and the future of services in the United Kingdom-a pilot survey.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Sanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The dual role of exosomes in renal fibrosis and their potential for clinical translational applications.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Rotation-traction manipulation versus cervical traction for axial neck pain caused by cervical degenerative disc disease: a multicenter randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Unichem
Pregabalin

Commercial impact

medium

The entry of Unichem into the market could lead to increased competition, potentially affecting revenue and market share for current Pregabalin products.

Regulatory impact

high

This approval indicates a significant regulatory milestone that could influence future applications and market dynamics in the neurology and pain management sectors.

What to watch

Monitor market entry timelines and any subsequent pricing strategies from Unichem.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.